Aiming to aid in the formulation of drug development strategies, eleven chapters are presented by Han (pharmacokinetics and clinical pharmacology sciences, Centocor R&D), Davis (Center for Metabolism Drug Discovery Unit, Cancer Research, GlaxoSmithKline), and Wang (drug discovery and chemistry, Georgia State U.) dealing with the key areas of pharmacokinetics and drug metabolism, pharmaceutical development, and safety assessment. The goal is to stress the integration of activities and information essential for the advancement of new medicines during drug development. The chapters specifically address pharmacokinetics in preclinical drug development, the role of membrane transporters in drug dispostion, cytochrome P450 and its application in drug discovery and development, the role of drug metabolism and metabolite identification in drug discovery, protein binding in drug discovery and development, prediction of pharmacokinetics in humans, pharmaceutics developability assessment, safety assessment in drug discovery, and assessment of strategies utilized to minimize the potential for induction of acquired long QT syndrome and the associated tachyarrhythmia known as Torsade de Pointes. Annotation 2010 Book News, Inc., Portland, OR (booknews.com)